Revascularization device market seen reaching $6.1 billion by 2030

The revascularization device market is projected to grow from $3.88 billion in 2025 to $6.1 billion by 2030, driven by rising cardiovascular disease, minimally invasive procedures and new imaging and stent technologies. North America led in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Revascularization devices help restore blood flow in blocked or narrowed arteries, supporting treatment for coronary artery disease and peripheral artery disease. - Rising cardiovascular disease rates are increasing demand for procedures and devices that reduce ischemia and lower the risk of heart attacks and strokes. - The market outlook signals continued investment in catheterization labs, interventional cardiology and outpatient vascular care.

What happened: - The Business Research Company released its Revascularization Device Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the market will rise from $3.88 billion in 2025 to $4.24 billion in 2026, a 9.3% CAGR. - The market is forecast to reach $6.1 billion by 2030, growing at a 9.5% CAGR. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report includes coverage of Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample is available through the company’s sample request page. - The full report is available on the company’s report page.

The details: - The market’s recent growth is tied to higher coronary artery disease rates, an aging population, more catheterization labs, wider use of drug-eluting stents and improvements in interventional cardiology. - Future growth is expected to come from precision-guided vascular interventions, minimally invasive surgery, AI-assisted interventional imaging, more ambulatory surgical centers and bioresorbable stents. - The report points to broader adoption of minimally invasive revascularization techniques and greater use of bioresorbable scaffolds in vascular repair. - The report also flags more imaging-guided interventions, increased radial access-based cardiovascular procedures and a shift toward outpatient vascular treatment. - Revascularization devices are designed to reopen or bypass vessel obstructions so oxygen-rich blood can reach tissues and organs. - The report cites cardiovascular disease as the main growth driver. - Cardiovascular disease includes coronary artery disease, stroke, heart failure and hypertension. - The report cites March 2025 data from the Joint Strategic Needs Assessment showing 185 cardiovascular disease deaths in 2023, up from 178 in 2022.

Between the lines: - The report suggests the market is moving from broad device adoption toward more specialized, image-guided and outpatient treatment models. - The focus on bioresorbable and next-generation stents points to demand for devices that can improve outcomes while reducing longer-term implant burden. - North America’s lead and Asia-Pacific’s growth outlook indicate a mature core market paired with expanding procedural access in faster-growing regions. - The added market attractiveness scoring, TAM analysis and forecasting dashboards show a stronger emphasis on decision-support tools for buyers and investors.

What's next: - The market is expected to keep expanding as minimally invasive vascular procedures become more common. - AI-assisted imaging and advanced intervention tools are likely to play a larger role in procedure planning and execution. - Growth in ambulatory surgical centers should support more outpatient vascular treatments. - The company says its 2026 reports now include new strategic additions such as company scoring matrix graphics, Excel-based forecasting dashboards and market hotspots infographics.

The bottom line: - Revascularization devices remain on a steady growth path as cardiovascular disease rises and care shifts toward less invasive, more technology-enabled treatment.